Second-line pazopanib effective in advanced RCC
Pazopanib demonstrated activity as a second-line treatment in patients with metastatic clear cell renal cell carcinoma who underwent first-line single-agent treatment with sunitinib or bevacizumab, according to results of a phase 2 trial.09/12/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology